In today’s briefing:
- Caris Life Sciences, Inc. (CAI): Peeking at the Prospectus of an AI TechBio IPO
- Intel @ BofA Securities 2025 Global Technology Conference
- Cantor Equity Partners SPACs: Crypto-Linked Opportunities with Political Ties
- Jefferson Capital Inc (JCAP): Peeking at the IPO Prospectus of PE-Backed Insolvency Account Manager
- VRA: 1Q Preview: Rebuilding Continues; Reiterate Buy Rating, $4 PT
Caris Life Sciences, Inc. (CAI): Peeking at the Prospectus of an AI TechBio IPO
- Sixth Street Partners is a significant investor in Caris Life Sciences and has been involved in multiple funding rounds since 2018.
- The company has more than 100 biopharma partners, such as Moderna, AbbVie, Xencor, and Merck KGaA.
- For the three months ended March 31, 2025 and 2024, they generated total revenue of $120.9 million and $80.7 million, respectively. The company also has significant net losses.
Intel @ BofA Securities 2025 Global Technology Conference
- Intel Products CEO Michelle Johnston Holthaus reveals that the company is now also including Samsung as a second foundry option
- The practice of Intel offering OEM incentives appears to be coming to the end of its unnatural life as LBT sets the tone. Great news for AMD I would think.
- Further investment in A14 capacity will now be contingent on having customers committing to taking up that capacity. No more build it and they will come a la Mr. Gelsinger.
Cantor Equity Partners SPACs: Crypto-Linked Opportunities with Political Ties
- CEPO and CEPT SPACs, run by Howard Lutnick, trade above trust value with potential multibagger upside in crypto-related deals.
- Cantor Fitzgerald, led by Lutnick’s son, has deepened its crypto involvement, including a 5% stake in Tether.
- Cantor’s SPACs feature no warrants, a sponsor note boosting trust value, and no specified target sectors.
Jefferson Capital Inc (JCAP): Peeking at the IPO Prospectus of PE-Backed Insolvency Account Manager
- They are a leading analytically driven purchaser and manager of charged-off and insolvency consumer accounts with four geographic regions with the majority of their operations landing in the USA.
- The principal purposes of this offering are to increase their capitalization and flexibility, facilitate an orderly distribution for the selling stockholders, and create a public market for their common stock.
- We anticipate this offering to likely find participation from sector dedicated investors and not draw the attention of “traditional” IPO players.
VRA: 1Q Preview: Rebuilding Continues; Reiterate Buy Rating, $4 PT
- We are reiterating our Buy, rating, $4 price target and projections for Vera Bradley with the company announcing 1QFY26 (April) results before the open on Wednesday.
- We believe Vera Bradley has continued to take steps to return to prominence, from returning key styles and features, adding more licensed items at both the main line and outlet stores and continuing to shift their looks to appeal to a younger customer base.
- Further, while the company remains impacted by the lag between loss of older customers and a shift to a younger group, management has been aggressive in reducing cash spend, which in the near term, unfortunately, has resulted in further main line store closures.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
